Literature DB >> 10792340

Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

T A Bachega1, A E Billerbeck, J A Marcondes, G Madureira, I J Arnhold, B B Mendonca.   

Abstract

OBJECTIVE: The diagnosis of the nonclassical form of 21-hydroxylase (NC-21OH) deficiency, established before molecular studies, is based on basal 17OH-progesterone (17OH-P) values > 15 nmol/l or ACTH-stimulated 17OH-P values > 30 nmol/l. This disease is caused by mutations in the structural gene that can be grouped into three categories: A, B and C, according to the predicted level of enzymatic activity. So, the genotype of the nonclassical form is a combination of mutations that cause moderate impairment of enzymatic activity in one allele and mutations which cause total (A), severe (B: 3%) or moderate (C: 20-60%) impairment of enzymatic activity in the other allele.
DESIGN: We analysed the influence of the different genotypes on 17OH-P levels in 58 patients with the nonclassical form of 21OH deficiency.
RESULTS: After screening for 18 mutations through Southern blotting, allele-specific polymerase chain reaction (PCR) and enzyme restriction, mutations were identified in 73% of the alleles. Patients with mutations identified in both alleles were divided into groups A/C (n = 18), B/C (n = 3) and C/C (n = 15). The basal and ACTH-stimulated 17OH-P levels in patients with A/C genotype ranged from 1.2 to 153 and 72-363 nmol/l, and in C/C genotype ranged from 0.9 to 72 and 51-363 nmol/l, respectively (P < 0.05 for stimulated levels). The lowest value of ACTH-stimulated 17OH-P levels in fully genotyped patients was 51 nmol/l. Patients with the A/C genotype presented androgen excess symptoms earlier than patients with the C/C genotype.
CONCLUSIONS: These data suggest an influence of genotype on phenotype and on 17OH-P levels. The high frequency of unidentified mutant alleles in nonclassical 21-hydroxylase deficiency suggests that ACTH-stimulated values of 17OH-P between 30 and 51 nmol/l have overestimated this diagnosis. Genotyping more patients with nonclassical 21-hydroxylase deficiency will help to redefine the cut-off value for ACTH-stimulated 17OH-P for correct diagnosis of this disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792340     DOI: 10.1046/j.1365-2265.2000.00995.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  18 in total

1.  Zona fasciculata 21-hydroxysteroids and precursor-to-product ratios in 21-hydroxylase deficiency: further characterization of classic and non-classic patients and heterozygote carriers.

Authors:  F A Costa-Barbosa; V M Carvalho; O H Nakamura; T A S S Bachega; J G H Vieira; C E Kater
Journal:  J Endocrinol Invest       Date:  2010-10-04       Impact factor: 4.256

2.  Non-functioning adrenal incidentalomas caused by 21-hydroxylase deficiency or carrier status?

Authors:  Henrik Falhammar
Journal:  Endocrine       Date:  2014-01-23       Impact factor: 3.633

3.  Genotype, phenotype and hormonal levels correlation in non-classical congenital adrenal hyperplasia.

Authors:  S Einaudi; E Napolitano; F Restivo; G Motta; M Baldi; G Tuli; E Grosso; N Migone; E Menegatti; C Manieri
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

4.  Replication of clinical associations with 17-hydroxyprogesterone in preterm newborns.

Authors:  Kelli K Ryckman; Daniel E Cook; Stanton L Berberich; Oleg A Shchelochkov; Susan K Berends; Tamara Busch; John M Dagle; Jeffrey C Murray
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

5.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline.

Authors:  Phyllis W Speiser; Ricardo Azziz; Laurence S Baskin; Lucia Ghizzoni; Terry W Hensle; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; Victor M Montori; Sharon E Oberfield; Martin Ritzen; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2010-09       Impact factor: 5.958

Review 6.  Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.

Authors:  Henrik Falhammar; Anna Nordenström
Journal:  Endocrine       Date:  2015-06-17       Impact factor: 3.633

7.  Genetic defects of the CYP21A2 gene in girls with premature adrenarche.

Authors:  N Skordis; C Shammas; A A P Phedonos; A Kyriakou; M Toumba; V Neocleous; L A Phylactou
Journal:  J Endocrinol Invest       Date:  2014-12-07       Impact factor: 4.256

Review 8.  Biochemical and genetic diagnosis of 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Anna Wedell; Anna Nordenström
Journal:  Endocrine       Date:  2015-09-04       Impact factor: 3.633

9.  A 31-year-old woman with infertility and polycystic ovaries diagnosed with non-classic congenital adrenal hyperplasia due to a novel CYP21 mutation.

Authors:  H Falhammar; M Thorén; K Hagenfeldt
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

10.  Genotype in the diagnosis of 21-hydroxylase deficiency: who should undergo CYP21A2 analysis?

Authors:  P Cavarzere; M Vincenzi; F Teofoli; R Gaudino; S Lauriola; E Maines; M Camilot; F Antoniazzi
Journal:  J Endocrinol Invest       Date:  2013-09-27       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.